IPO: Nuvectis Pharma, Inc. Date: 04 February 2022

Symbol: NVCT
Industry: Biotechnology
Exchange: NASDAQ
IPO Price Low: $5
IPO Price High: $7

Nuvectis Pharma is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. We rely on our core competencies of target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Improved genetic sequencing and understanding of cancers’ RNA, DNA and protein abnormalities has led to the discovery and characterization of novel oncogenic genetic mutations and alterations that were previously unknown, unaddressed, unsuccessfully targeted or overlooked. We believe that these advancements represent a fundamental change in the development of targeted therapies and will increasingly lead to tumor agnostic approaches whereby cancers will be characterized for treatment based on genetic signatures, such as a certain mutation, rather than in a tissue-specific manner. We are currently developing two preclinical drug candidates with the lead candidate expected to begin a Phase 1 clinical trial in the fourth quarter of 2021.

Shares Offered: 2083333
Shares Outstanding: 11601127
Market Cap: 69606762

How to buy Nuvectis Pharma, Inc. stock

For more information on the Nuvectis Pharma, Inc. IPO please sign up using the form opposite.

IPO Exchange is dedicated to providing accurate information to help you make the best investment decisions and expand your portfolio.

Get more details on how you can invest in Nuvectis Pharma, Inc. by signing up below.